Table 5 Maternal median (25–75 percentile) urinary phthalate metabolite concentrations among offspring with or without allergic outcomes
Outcome | n | MEP Median and 25–75 (ng/mL) | ΣMBPi + n Median and 25–75 (ng/mL) | ΣDEHPm Median and 25–75 (ng/mL) | ΣDiNPm Median and 25–75 (ng/mL) |
|---|---|---|---|---|---|
Wheeze within the last 2 years | |||||
Yes | 123 | 21.9 (9.6–56.9) | 39.7 (25.4–71.5) | 22.3 (12.2–33.8) | 9.4 (5.4–15.2) |
No | 429 | 20.3 (9.0–51.9) | 45.2 (27.0–70.0) | 21.8 (13.7–32.3) | 9.2 (5.4–19.1) |
Self-reported asthma | |||||
Yes | 25 | 19.3 (12.7–67.2) | 41.9 (30.2–71.5) | 22.3 (13.9–33.8) | 10.7 (5.1–22.3) |
No | 510 | 21.4 (9.1–52.5) | 44.5 (26.6–68.5) | 21.8 (13.5–32.4) | 9.2 (5.4–18.3) |
Doctor-diagnosed asthma | |||||
Yes | 27 | 16.4 (6.8–55.5) | 36.9 (18.3–74.2) | 23.1 (9.3–31.9) | 10.3 (4.0–22.3) |
No | 503 | 21.8 (9.3–52.5) | 44.8 (27.1–68.5) | 21.9 (13.5–32.8) | 9.3 (5.4–18.4) |
Use of medicine for asthma/cold | |||||
Yes | 76 | 21.8 (10.3–66.3) | 38.7 (30.0–64.2) | 20.6 (9.6–32.6) | 8.6 (5.0–14.1) |
No | 476 | 20.7 (9.1–52.0) | 45.2 (26.3–71.3) | 22.0 (13.5–32.4) | 9.4 (5.5–19.2) |
Self-reported eczema | |||||
Yes | 57 | 16.0 (8.9–35.4) | 43.5 (24.8–63.3) | 9.6 (5.1–20.7) | 21.5 (13.4–31.3) |
No | 430 | 22.2 (10.2–55.5) | 44.5 (27.2–68.5) | 9.4 (5.5–19.0) | 22.2 (13.7–33.4) |
Doctor-diagnosed eczema | |||||
Yes | 32 | 14.4 (8.6–35.2) | 43.1 (19.9–60.4) | 9.6 (4.7–22.7) | 20.3 (12.1–31.8) |
No | 455 | 22.2 (9.7–55.0) | 44.6 (27.2–69.2) | 9.4 (5.5–18.8) | 22.3 (13.8–33.2) |
Use of medicine against eczema | |||||
Yes | 24 | 18.2 (8.57–38.8) | 40.0 (23.6–62.5) | 11.0 (4.7–36.1) | 21.4 (13.4–32.7) |
No | 366 | 23.7 (10.6–55.6) | 44.3 (27.9–68.5) | 9.7 (5.7–18.0) | 22.1 (14.0–33.4) |
Self-reported rhinitis | |||||
Yes | 49 | 17.8 (9.1–43.1) | 49.9 (32.0–81.9) | 25.2 (16.7–32.1) | 11.2a (7.1–21.5) |
No | 483 | 21.2 (8.9–55.0) | 44.1 (26.6–68.5) | 21.8 (13.5–33.0) | 9.0 (5.2–18.0) |